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Abstract
Placebo’s (positive expectancies producing positive outcomes) and nocebo’s (negative
expectancies producing negative outcomes) are real and measurable effects. Real as
these effects may be, predicting individuals that may be susceptible to placebo/nocebo
effects has been inconsistent. The present study examined whether measures designed
to assess somatization (MSPQ), catastrophizing (PCS) and childhood trauma (CTQ)
would predict placebo and nocebo membership. In addition, measures designed to
assess anxiety (ASI) anxiety about pain (PASS) and depression (BDI) were evaluated
to determine whether anxiety or depression mediates responsiveness. The Hargreaves
Thermal Withdrawal test and the submaximal effort tourniquet technique were employed
as pain vehicles for the measurement of group differences. No significant effects of
planned analyses were observed. However, unplanned analyses of childhood trauma
subscales indicated that physical and emotional abuse predicted placebo response.
Additionally, emotional neglect trended toward predicting nocebo responsiveness.
These results indicate that further studies, correcting for weaknesses, is warranted.

Keywords: placebo, nocebo, somatization, catastrophizing, childhood trauma, anxiety
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Introduction
Placebo (I will please) and nocebo (I will harm) are real phenomenon that have
been extensively studied but are not well understood (Benedetti et al. 2007). The term
placebo is practically ubiquitous in contemporary language and has a lengthy history.
The use of the word placebo dates back several centuries in medical literature with the
first reported controlled placebo study conducted in 1799 (Price, Finniss, & Benedetti,
2008). Geers, Helfer, Kosbab, Weiland and Landry (2005) pointed out that “placebos
have been described as one of the most powerful agents of symptom relief in medicine”
and argue that prior to the beginning of the 20th century most treatments for illness and
disease were placebo.
Nocebo, on the other hand, is a newer term that is rarely used in lay language or
academia. According to Benedetti and Amanzio (1996) the term nocebo was introduced
by Kissel and Barrucand in 1974 to distinguish “the pleasing and salubrious effects of
placebo from the noxious effects.” This distinction, though important, does little to
eliminate confusion between the two terms. For example, if one does a PubMed search
for nocebo, large numbers of papers will be found with placebo in the title and nocebo in
the text. It seems clear that the field generally considers nocebo to fall under the
umbrella of placebo, an assumption that may be dispelled by considering precise
definitions of the two terms. As noted by Grünbaum (1981), a fundamental problem to
advancing the field of placebo research has been one of definition.
Important Distinctions
The author will begin by clarifying the difference between placebo and the
placebo effect. While it may seem intuitive that there is a difference, the distinction is
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often muddled or missing in related literature. For example, Olchansky (2007) states a
“placebo is a sham, often a pill, but any intervention purported to be therapeutic.
Without direct physiologic or pharmacologic activity, a placebo somehow provides
benefit or apparent benefit. Nocebo is a sham, without direct physiologic or
pharmacological activity, that causes harm or apparent harm.” Note the lack of
distinction for placebo effect.
On the other hand, Stewart-Williams and Podd (2004) posited the following
definitions that included such a distinction. “A placebo is a substance or procedure that
has no inherent power to produce an effect that is sought or expected.” Followed by a
definition for placebo effect, “A placebo effect is a genuine psychological or
physiological effect, in a human or another animal, which is attributable to receiving a
substance or undergoing a procedure, but is not due to the inherent powers of that
substance or procedure.”
Benedetti, Carlino and Pollo (2010) echo the immediately preceding definition by
stating “A real placebo effect is a psychobiological phenomenon occurring in the
patient’s brain after the administration of an inert substance, or of a sham physical
treatment such as sham surgery, along with verbal suggestions (or any other cue) of
clinical benefit.” Colloca and Benedetti (2007) then state for nocebo and nocebo effect
the following, “If positive verbal suggestions, which are typical of the placebo effect, are
reversed in the opposite direction, a nocebo effect can be obtained. Therefore, the
study of the nocebo effect is the study of the negative psychosocial context around the
patient and the treatment, and its neurobiological investigation is the analysis of the
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effects of this negative context on the patient’s brain and body.” In short, nocebo is the
opposite of placebo either with pill or procedure and its observed effect or effects.
Taken together, the Stewart-Williams and Podd definitions provide the most
complete framework from which to work. Now one only needs to make a minor
amendment to clarify the meaning of nocebo and nocebo effect:
A placebo or nocebo is a substance or procedure that has no inherent
power to produce an effect that is sought or expected.
A placebo effect is a genuine positive psychological or physiological effect,
in a human or another animal, which is attributable to receiving a
substance or undergoing a procedure, but is not due to the inherent
powers of that substance or procedure. A nocebo effect is a genuine
negative psychological or physiological effect, in a human or another
animal, which is attributable to receiving a substance or undergoing a
procedure, but is not due to the inherent powers of that substance or
procedure.
The author argues that the amendment is necessary because it provides effect
directionality and thus, more clearly, delineates placebo from nocebo. Now that working
definitions for placebo and nocebo have been established, the remaining discussion will
encompass a brief review of issues related to placebo/nocebo effects, pain and its
relationship to the placebo response.
What is known: A brief review.
Much of the knowledge of the placebo effect comes from pain studies with and
without neuropharmacological approaches (Amanzio and Benedetti, 1999; Benedetti &
Amanzio, 1997; Hoffman et al., 2005). The literature generally suggests that placebo
and nocebo responses are a function of conditioning and/or expectation (Benedetti et
al., 2003; 2007; Colloca and Benedetti, 2007; Colloca et al. 2008; Enck et al. 2008;
Geers et al., 2006; Klosterhalfen and Enck, 2008; Klosterhalfen et al., 2009; Olshancky,
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2007; Stewart-Williams, 2004; Stewart-Williams and Podd, 2004; Voudouris et al.,
1990),with reward, social learning and memory also implicated (Benedetti, Carlino &
Pollo, 2010).
Expectancy
Expectancy theory has gained ground in recent years, largely supplanting similar
mental constructs such as faith and hope (Peck & Coleman, 1991). Expectancy as a
construct embodies an intuitive understanding of what the placebo effect is, “A placebo
produces an effect because the recipient expects it to. The placebo elicits an
expectation for a particular effect, and the expectation produces that effect” (StewartWilliams and Podd, 2004).
Benedetti, Carlino & Pollo (2010) highlight two studies that demonstrate how
strongly expectation is linked to pain and placebo responsiveness. Both studies
investigated the role of the prefrontal cortex and placebo responsiveness. In the first
study, Benedetti et al. (2006) studied Alzheimer patients in initial stages and after one
year to evaluate the effectiveness of a placebo component of therapy the patients were
receiving. The placebo component of therapy was correlated with a cognitive status as
assessed by the Frontal Assessment Battery (FAB) test and functional connectivity
among different brain regions assessed by electroencephalographic connectivity
analysis. It was found that patients with lower FAB scores had lower placebo treatment
responsiveness. Additionally, it was observed that disruption of placebo responsiveness
occurred at the same time that prefrontal lobe connectivity to the rest of the brain was
reduced.
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Next, Krummenacher et al. (2010) used repetitive transcranial magnetic
stimulation (rTMS) to transiently disrupt right and left dorsolateral prefrontal cortex (r/l
dlpfc) functioning in a heat pain paradigm. This study found that placebos significantly
increased pain threshold/tolerance and that disruption of r/l dlpfc using rTMS completely
blocked placebo analgesia. In other words, “no prefrontal control, no placebo response”
(Benedetti et al., 2010).
Conditioning
Classical conditioning comprises the second major theoretical approach to the
placebo effect. In general, applying conditioning to the placebo effect requires the drug
or active ingredient to be the unconditioned stimulus (US) and the unlearned response
to the active ingredient to be the unconditioned response (UR). In the course of any
number of paradigms, the US would be paired with a neutral stimulus such as pill
casings, syringes or even to objects, places, people and the procedures themselves.
Through repeated associations with the US the neutral stimuli become conditioned
stimuli (CS) capable of producing an effect similar to that of the active ingredient, which
would be considered a conditioned response (CR). Thus, in a conditioning framework
the placebo would be considered the CS and the placebo effect the CR (StewartWilliams and Podd, 2004).
Much of the support for the classical conditioning paradigm comes from research on
nonhuman animals and has been demonstrated with a variety of drugs and systems.
Hernstien (1962) demonstrated that rats conditioned with injections of amphetamines
when injected with saline exhibited behavior similar to that seen by amphetamine
injection. Ader and Cohen (1975) paired novel saccharine flavored liquid with
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cyclophosphamide, an immunosuppressant. After several pairings, the saccharine
solution (CS, placebo) would elicit immunosuppression (CR, placebo effect). This was
groundbreaking work as it was not generally believed at the time that conditioning could
affect the immune system (Stewart-Williams and Podd, 2004).
As with many academic topics, scholars tend to prefer one theory over another, in this
case pitting expectancy (Kirsch, 1991) against conditioning (Voudouris et al., 1989;
1990). However, as with many dichotomies there is often the overlooked third choice of
both. In 2003, Benedetti et al. demonstrated in experimental pain models and Parkinson
models that “conditioning is actually mediated by expectations and that expectations do
not affect conditioned responses.” While it may not be clear what relationship
expectancy and conditioning might have with each other, the literature shows that
expectancy or previous exposure (conditioning) or both are necessary for the placebo
effect to take place.
Mechanisms and diseases
Pain, as previously mentioned, is the paradigm utilized most when studying
placebo and nocebo effects. It provides an easy platform from which to manipulate
variables. This flexibility has enabled researchers to articulate the neurological
mechanisms involved with pain and placebo/nocebo responses. It has been
demonstrated placebos activate endogenous opioids (analgesia) that decrease pain
response and nocebos activate an opponent hyperalgesic nonopioid system
(cholecystokinin, CCK) that increase pain responsiveness (Amanzio and Benedetti,
1999; Benedetti, 2007; Benedetti & Amanzio, 1997; Benedetti et al., 2007; Colloca and
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Benedetti, 2007; Colloca et al., 2008; Enck et al., 2008; Klosterhalfen and Enck, 2008;
Kong et al., 2008).
Though pain has been one of the most intensively studied areas of placebo and
nocebo, a number of other conditions have been studied using a placebo paradigm. As
a result, researchers are better able to articulate the mechanisms involved. Next to pain,
Parkinson’s disease has been well described and studied in placebo settings. It is
generally thought to generate an expectation induced release of dopamine in the
striatum and recorded changes of firing patterns of sub-thalamic nucleus neurons as a
result have been observed (Benedetti et al., 2004). According to Benedetti’s (2008)
review of placebo and placebo effects across diseases and treatments, depression has
differential metabolic responses in different brain regions, thought to be related to
inhibition of serotonin reuptake. Furthermore the review showed that addiction had
demonstrated changes in metabolic activity in various brain regions and the
cardiovascular system has demonstrated reductions of β-adrenergic activity, all in
response to placebo. Additionally, it was also shown that conditioning of opioid
receptors in respiratory centers has been seen as a result of pharmacological
preconditioning and the immune system has been documented to respond to
pharmacological preconditioning as well, especially to immunosuppressive drugs.
Finally, it was reported that conditioning of some hormones has been observed for the
endocrine system as a result of pharmacological preconditioning with 5-HT receptor
agonists.
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Arguments against the placebo effect
Despite the wealth of evidence documenting real placebo and nocebo effects, it
is important to note that the literature is not consistent. Three meta-analytic studies
have shown that depending on design placebo effect sizes can range from small in
placebo only treatment designs (Hrobjartssen & Gøetsche, 2001; 2004) to large effect
sizes in analgesic pain studies (Hrobjartssen & Gøetsche, 2006). These studies suggest
that many placebo effects can be attributed to poor study design, spontaneous
remission and regression to the mean and is, therefore, not as ubiquitous as the
literature might suggest or even non-existent. Though it is important to note that poor
design, remission and statistical regressions could influence the effect size of placebo
response, it is also important to note that these meta-analyses have been challenged on
a number of methodological issues. The primary complaint was one of directly
comparing conditions that are not readily comparable (Meissner et al., 2007; StewartWilliams and Podd, 2004). Regardless of the effect size that may or may not be
observed in a particular set of studies it is clear that the literature as a whole considers
the placebo and nocebo effects to be real effects and one of serious academic inquiry.
Susceptibility to the placebo and nocebo effect
Scholars like Liberman (1968) and Jospe (1978) have endeavored to find
evidence of a placebo-prone personality. The results, however, have been generally
weak and insignificant (Gelfand, Gelfand & Rardin, 1965; Shapiro and Shapiro, 1997;
Turner et al., 1994) or inconsistently present across different trials (Kaptchuk et al,
2008). Geers et al. (2005) suggested that basic methodological problems, poor
instrument reliability and factors such as spontaneous remission or regression to the
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mean rather than a placebo effect may be impacting whether or not placebo personality
traits or situations can reliably emerge. These are the same problems mentioned in the
studies by Hrobjartsson and Gøtzsche (2001, 2004, 2006) and recognized by others
(Stewart-Williams, 2004; Stewart-Williams and Podd, 2004; Enck, Benedetti &
Schedlowski, 2008; Benedetti, Carlino & Pollo, 2010).
The literature is clear, however, that placebo responders do exist. Kosterhalfen
and Enck (2008) report that the overall placebo response rate to be around 40%, with
variations on response rates depending on the disorder examined. For example,
response rates of 29% in depression and 21% in migraine prophylaxis were reported
while response rates of 26.9% to 56% were found in pain studies (Price, Finniss &
Benedetti, 2008) and 75% placebo response rates found in a metaanalytic study of antidepressive medication trials by Kirsch and Sapirstein (1998).
Recently, two genetic studies have tried to identify placebo responders. One
study examined genetic variants related to serotonin and its role in placebo responding
and social anxiety. It was found that only subjects homozygous for the long allele of the
5-HTTLPR (serotonin transporter-linked polymorphic region) or the G variant of the
TPH2 (tryptophan hydroxylase-2) gene promoter G-703T exhibited reduced stress
related activity in the amygdala during placebo response. Additionally, the TPH2
polymorphism was found to be a significant predictor of clinical placebo response
(Furmark et al. 2008). The next genetic study examined the relationship between
placebo responsiveness and polymorphisms in genes encoding for the monoamines
catechol-O-methyltransferase (COMT) and monoamine oxidase A (MAO A) in
participants with major depressive disorder. It was found that individuals with G or G/G
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forms of MAO A had significantly lower magnitude of placebo response compared with
other genotypes and that individuals with the ValMet COMT polymorphism showed a
trend toward lower magnitude of placebo response (Leuchter et al. 2009). Exciting as
finding placebo responders through genetic techniques may be additional studies are
needed to confirm and elaborate these results.
In General, research that utilizes placebo is assessing medical treatment
effectiveness by comparing active treatment groups with placebo groups but not with a
no-placebo control group (Geers et al., 2006; Ader, 2000). Less than 4% of placebo
studies have included a no-placebo control group in which to evaluate the effect claimed
(Ernst and Resch, 1995; Fisher, 2000; Geer et al., 2005). A major problem with omitting
a no placebo group is that it calls into question the comparative accuracy of the effect
sizes observed and reported in such groups. Given this problem, the certainty that no
consistent placebo responder can be found is called into question.
Pain as a Vehicle for Understanding Placebo and Nocebo
Pain is mentioned throughout this paper as the most understood and articulated
modality for placebo and nocebo effects. It is a useful paradigm for examining these
effects as it is easily manipulated in experimental situations and avoids some ethical
dilemmas that may be seen in other placebo/nocebo studies (e.g. giving suggestions of
symptom worsening to major depressive individuals). It is necessary then to discuss
briefly pain and factors that are known to influence it.
The International Association for the study of Pain (IASP) has defined pain as
“an unpleasant sensory and emotional experience associated with actual or potential
tissue damage, or described in terms of such damage” (Merskey and Bogduk, 1994).
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Loeser and Melzack (1999) describe three broad categories of pain. 1) Transient pain,
which is elicited by activation of nociceptive transducers in the skin and other tissues of
the body but do not require tissue damage. This type of pain is ubiquitous in daily life
and is rarely a cause in seeking health care. 2) Acute pain, which is activated by
substantial injury of bodily tissue and the activation of nociceptive transducers at the
local site of tissue damage. Individuals typically seek medical care for this type of injury.
3) Chronic pain, which is pain that is commonly triggered by an injury or disease and is
commonly perpetuated by factors other than the cause of the pain. Loeser and Melzack
(1999) further suggest that all types of chronic pain lead people to seek health care,
however treatment is often not effective. They state that chronic pain is unrelenting and
attribute this to stress, environmental and affective factors that may be superimposed
on the original damaged tissue, contributing to its intensity and persistence.
The American academy of Pain Management (2003) claims that for the previous
year approximately 57% of adult Americans reported experiencing recurring or chronic
pain, 62% of which reported being in pain for more than one year with 40% noting they
were in constant pain. Gatchel (2004a, 2004b) indicates the pervasive nature of pain is
a medical problem by stating that it affected over 50 million Americans, incurs a cost of
over $70 billion annually in health care and lost productivity and accounts for more than
80% of all clinical visits. Indeed the U.S. congress, in recognition of the problem,
declared 2001-2010 as the Decade of Pain Control and Research. Further, the Joint
commission on Accreditation of Healthcare Organization has implemented a
requirement that physicians consider pain to be the fifth vital sign, in addition to pulse,
blood pressure, core temperature and respiration (Gatchel et al. 2007).
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Nonphysiological Factors that Influence the Experience of pain
Pain has an urgent primitive quality that is responsible for its emotional qualities
that are unlike any other sensory experience and the intensity with which it is
experienced can be affected by a number of subjective experiences that produce
differing responses by individuals under comparable circumstances (Kandel, Schwartz
and Jessel, 2000). Conceptually there are a number of nonphysiological factors that can
influence the perception of pain, for this discussion the factors being considered are
anxiety, catastrophizing, somatization, depression and childhood trauma.
Anxiety
Anxiety is generally considered to be worry about future events and can lead to
misinterpretation of body states, a generalized state of worry, phobias or specific
disorders related to specific traumatic events (DSM-IV-TR; American Psychiatric
Association, 2000). It is known to have physiological effects such as increased arousal
(Cuthbert et al., 2003), and has been demonstrated to have a significant impact on the
perceived intensity of painful stimuli, specifically in the context of placebo and nocebo
studies (Colloca & Benedetti, 2007; Benedetti et al., 2006). It has been demonstrated
that reduction of anxiety in placebo studies will reduce pain perception and that
increases in anxiety during nocebo studies will increase pain perception (Benedetti and
Amanzio, 1997; Benedetti et al., 1997; Benedetti et al., 2006; Colloca and Benedetti,
2007)
Because of its strong association with pain and pain perception (Benedetti et al.,
2006; 2007; Colloca and Benedetti, 2007; Gatchel et al., 2007; Geers et al., 2005;
Keogh et al., 2006; Loeser and Melzack, 1999; Ploghous et al., 2001) and the degree to
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which it has been experimentally manipulated made anxiety an examined variable in
this study.

Catastrophizing
Catastrophizing is considered a tendency to exaggerate, focus and emphasize
negative aspects of painful situations (Turner & Aaron, 2001). It has been characterized
as a coping mechanism and appraisal or belief system (Sullivan et al., 2001).
Individuals with a tendency to catastrophize are thought to reflect a persistent life
course trait (Sullivan, Bishop & Pivik, 1995).
Sullivan et al. (2008) conducted a study to evaluate the relationship between
catastrophizing and placebo responsiveness and found that high catastrophizers were
more likely to respond to placebo suggestion than low catastrophizers and while
receiving active treatment high catastrophizers responded significantly less than low
catastrophizers. This suggests that catastrophizers may be more susceptible to nocebo
suggestions than non-catastrophizers. Due to its consistent relationship to painful
situations, well-articulated foundation and the important role it plays in the perceived
intensity of painful experience and emotional distress (Sullivan et al., 2001),
catastrophizing was a variable of interest in this study.
Somatization
It is important to understand that certain patients use their physical
symptoms as a way of dealing with, and communicating about, their
emotional lives (somatization). That is to say, in this type of symptom
magnification, physical symptoms may be easier to accept as causing
current unhappiness and discontent than admitting that some
psychological reason is contributing to it (Gatchel, 2004).
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Geers, Helfer, Wieland & Kosbab (2006) examined the role somatic focus might have in
placebo responders. They hypothesized that somatic focus would influence the
response rates of individuals in an unconditional situation as compared to individuals in
a conditional situation or controls. Results indicated that individuals given an
unambiguous (unconditional) situation and told to focus on physical symptoms (somatic
focus) were indeed more likely to report more placebo symptoms than the other two
groups.
This study suggests that somatizer’s would be susceptible to both placebo and
nocebo effects due to their attention to physical changes by definition. Because of
somatization’s relationship to pain as a coping mechanism and the influence it may
have on placebo/nocebo effects, it was considered a factor in this study.
Depression
Depression is another psychological factor whose relationship to pain cannot be
ignored. A literature review by Bair, Robinson, Katon and Kroenke (2003) found that on
average 65% of patients with depression experienced one or more pain symptoms and
that depression was observed in anywhere from 5 to 85% of patients with pain
conditions.
As mentioned earlier, the meta-analysis conducted by Kirsch and Sapirstein
(1998) indicating a 75% placebo response rate in anti-depressive medication trials
dictates that depression needed consideration as a variable in this study.
Childhood Trauma
Of additional interest is the consideration the role childhood trauma may have on
pain perception. Research has demonstrated that early childhood trauma and adversity
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is predictive for the onset of back pain in adulthood (Kopec and Sayre, 2005) and has
been related to poor outcome following back surgery (Shofferman et al., 1993). It is
believed that childhood trauma involving abuse or neglect may influence the way one
perceives future painful events (Fillingim and Edwards, 2005; Heckman and Westefeld,
2006) based on past experiences and was therefore included as a consideration in this
study.
Purpose and hypotheses
Given the information presented thus far, it is the author’s goal to evaluate whether the
nonphysiological factors of anxiety, catastrophizing, somatization, depression and
childhood trauma will influence an individual’s response to placebo and nocebo
conditions. This study evaluated these factors using a placebo group, nocebo group and
control group design, which allowed the clearest distinction between groups.
Based on evaluation of material presented to this point the author hypothesized
that subjects given an inert pill and a positive verbal suggestion (placebo) will report
experiencing less pain than controls and that subjects given an inert pill and negative
verbal suggestion (nocebo) will report experiencing more pain than controls in a study
utilizing ischemic arm pain,. Additionally, based on the literature, it is the author’s
assertion that somatization, catastrophizing and childhood trauma represent a stable
coping style and unchanging personal experiences, respectively, where anxiety and
depression represent transient variable states. Given this assertion, the author
hypothesized that individuals in the top ten percent of somatizers (high somatizers) will
report lower levels of pain in the placebo condition in comparison to the bottom fifty
percent of somatizers (low somatizers) and controls with the top ten percent reporting
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higher pain ratings in the nocebo condition than the bottom fifty percent and controls. In
the case of childhood trauma, the author suggests that these negative experiences will
present a negative outlook (expectation) in painful situations. Thus, it was hypothesized
that individuals in the top 10 percent of trauma victims (high trauma) will report higher
pain ratings in the nocebo condition as compared to those in the bottom 50 percent (low
trauma) and those in placebo and control conditions. In addition, it is hypothesized that
anxiety and depression will mediate responses to the Nocebo and Placebo groups.
Methods
Participants
90 healthy participants, 62 females and 28 males, were recruited from
psychology classes at the University of New Orleans and randomly assigned to one of
three groups (nocebo, placebo and control) after screening for chronic or current pain,
to include back pain, neuropathic pain and headaches; mental distress; cardiovascular
disorders; asthma; arthritis; as well as those who indicate they have taken aspirin or any
other analgesic (prescription or over the counter), cough medicine, sedatives,
tranquilizers, antidepressants or alcohol consumption on the day of testing. Following
the screening process all subjects signed a written informed consent form in which the
experimental procedure was described in detail.
An evaluation of a large data set from a questionnaire distributed at the
University of New Orleans (2008) that contained two of the questionnaires to be
included in this study (the MSPQ and PCS), was conducted to determine the minimum
number of participants that would be required to conduct this study. Results indicated
that 135 participants (45 per group) is the minimum number necessary for reasonable
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assurance that random assignment to each group will include enough members for
each variable to allow comparisons. The proposed number of 135 participants was
approved by committee, however, due to unanticipated time constraints the number or
participants at the time of writing is 90.
Measures
Modified Somatic Perception Questionnaire.
The MSPQ is administered to measure somatic arousal. It is a 13 item 4-point
Likert scale ranging from 1 (not at all) to 4 (very much) that demonstrates adequate
validity and reliability (Main, 1983).
Pain Catastrophizing Scale.
The PCS is a 13 item 5-point Likert scale ranging from 0 (not at all) to 4 (all the
time). It assesses pain related catastrophizing by asking individuals to recall painful
experiences and rate the frequency with which they experience catastrophic thoughts
and feelings. The PCS has well established reliability and validity (Osman et al, 2000;
Sullivan, 1995).
Childhood Trauma Questionnaire.
The CTQ is a 28 item scale indicating levels of retrospective childhood abuse
and neglect. It contains four scales (physical and emotional abuse, emotional neglect,
sexual abuse, and physical neglect) containing 5-point Likert scale items ranging from
0 (never) to 4 (very often). The CTQ has demonstrated adequate reliability and
construct validity (Rosen and Martin, 1996).
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Anxiety Sensitivity Index
The ASI is a 16 item questionnaire designed to assess the tendency to fear
anxiety-related bodily sensations based on the belief they may have harmful
consequences. Each item is rated on a 5 point Likert scale rating from 0 (very little) to 4
(very much). The ASI has good validity and reliability and has been shown to predict
fear of pain, escape and avoidance behaviors (Asmundson and Carleton, 2005;
Asmundson and Taylor, 1996; Norton and Asmundson, 2004).
Pain Anxiety Symptoms Scale.
The PASS is a valid 20-item questionnaire that measure anxiety associated with
pain. Each item is rated on a 6-point Likert scale ranging from 0 (never) to 5 (always).
The PASS possesses adequate construct and concurrent validities (Staats et al., 2001).
Beck Depression Inventory.
The BDI is one of the most widely used instruments for depression screening in
psychiatric patients and normal populations (Whisman, Perez & Ramel, 2000). The BDI
consists of 21 items on a 4-point Likert scale ranging from 0 to 3, with greater
responses indicating greater degrees of depression. Scores are summed to yield a
score of 0 to 63.
Pain measures
Hargreaves Thermal Withdrawal Test.
This test measured phasic (brief escapable pain). Subjects were asked to place their
non-dominant hand, palm-down, on a glass table suspended above a halogen heat
source. Subjects were asked withdraw when they can no longer tolerate the
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temperature. Latency to withdraw was recorded. If subjects failed to withdraw, the light
was terminated after 20 seconds to prevent tissue injury.
Modified Submaximal Tourniquet Procedure.
This test induced exercise ischemic pain in the arm that increases over time
(Amanzio and Benedetti 1999; Benedetti, 1996; Benedetti et al., 2006; Smith et al.,
1966). The pain felt is that of a strong cramp similar to what one might experience
during a strenuous workout. Subjects had the venous blood of the non-dominant arm
exsanguinated by elevating it above the heart for 30 seconds, after which a
sphygmomanometer (blood pressure cuff) was placed around the upper arm. The
pressure cuff was inflated to a pressure of 300 mmHg. After this the subject was asked
to start squeezing a hand exerciser 12 times, each squeeze to last 2 seconds followed
by a 2 second rest. The discomfort experienced increases over time and the subject
was asked to rate the intensity of their discomfort on a visual analog scale rating from 0
(no pain) to 10 (worst possible pain) every minute until conclusion. At the five minute
mark subjects were asked to squeeze the hand exercise 5 more times and twice more
at the eight minute mark. The test continued until the subject indicated a desire to
withdraw or a maximum of 10 minutes have elapsed. Once a desire to withdraw has
been verbally indicated the pressure cuff was immediately removed. Time to withdraw
and intensity ratings were recorded.
Procedure
Qualified participants in all conditions had both sensory measures explained to
them in detail and a brief description of the “drugs” to be given. Next, each subject was
given the Hargreaves Thermal Withdrawal test for a base line measurement. Once the
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Hargreaves test was conducted each subject was given the MSPQ, PCS and CTQ
respectively. Upon completion of these three assessment measures each participant
rolled three di numbering from one to three in a variety of colors. The participant would
then show the experiment what blue number di they had drawn and was lead to believe
that this determined which experimental group they had been assigned to. The purpose
of which was to allow participants to have a sense of control in the selection process.
The true assignment, however, had been randomly predetermined.
Following the “randomization” process the experimenter left the room to retrieve
the “drug” of study which in each case was a size 4 red and white colored gelatin
capsule containing pure cornstarch. Upon returning, the experimenter explained to the
participant which drug they were to receive and any potential side effects.
Placebo group.
Subjects assigned to this group were told that they would were told the following
“For the next part of the study you will be given an anxiolytic, which is a drug that
reduces anxiety. This drug (P-533), in addition to reducing anxiety, has been
documented to be a pain reliever as well. This drug is safe and has no negative
reactions with other medication. It can have the following side effects: sense of
wellbeing and occasional reports of drowsiness.” After consumption of the pill
participants were left alone in the testing room without distractions (e.g. cell phones,
ipods) for 15 minutes to give the “drug” time to take effect. While in truth the purpose of
the lapse was to allow participants time to ruminate over the coming pain measures for
15 minutes, which presumably increased test anxiety and increasing group divergence
allowing for easier statistical discrimination.
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After 15 minutes had elapsed the experimenter returned to give the remaining
questionnaires, which consisted of the ASI, PASS and BDI, respectively. Once the
questionnaires were completed subjects were given a 2nd Hargreaves test followed by
the tourniquet procedure. After conclusion of the pain measures participants were
thanked for their time and dismissed. Due to the possibility of participant contamination
full debriefings are to be conducted at the end of the study. Participants will be
contacted by email (obtained from informed consent forms) and fully debriefed at that
time.
Nocebo group.
Subjects assigned to this group were told the following “For the next part of the
study you will be given a vasoconstrictor, a drug that constricts the blood vessels. This
drug (N-3556) has been documented to increase pain sensitivity in certain situations,
specifically with ischemic pain and heat. This drug is safe and has no negative reactions
with other medication. However, it can have the following side effects: increased heart
rate, mild headache, increased anxiety and constipation have all been reported. These
effects have all been documented to be short lived, however.” After consumption of the
pill participants were left alone in the testing room without distractions (e.g. cell phones,
ipods) for 15 minutes to give the “drug” time to take effect. While in truth the purpose of
the lapse was to allow participants time to ruminate over the coming pain measures for
15 minutes, which presumably increased test anxiety and increasing group divergence
allowing for easier statistical discrimination.
After 15 minutes had elapsed the experimenter returned to give the remaining
questionnaires, which consisted of the ASI, PASS and BDI, respectively. Once the
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questionnaires were completed subjects were given a 2nd Hargreaves test followed by
the tourniquet procedure. After conclusion of the pain measures participants were
thanked for their time and dismissed. Due to the possibility of participant contamination
full debriefings are to be conducted at the end of the study. Participants will be
contacted by email (obtained from informed consent forms) and fully debriefed at that
time.
Control group.
Subjects assigned to this group were told the following “For the next part of the
study you will be given an inert talc pill. This pill has no active effects and is being given
to you because you have been assigned to a control group.” After consumption of the
pill participants were left alone in the testing room without distractions (e.g. cell phones,
ipods) for 15 minutes to give the “drug” time to take effect. While in truth the purpose of
the lapse was to allow participants time to ruminate over the coming pain measures for
15 minutes, which presumably increased test anxiety and increasing group divergence
allowing for easier statistical discrimination.
After 15 minutes had elapsed the experimenter returned to give the remaining
questionnaires, which consisted of the ASI, PASS and BDI, respectively. Once the
questionnaires were completed subjects were given a 2nd Hargreaves test followed by
the tourniquet procedure. After conclusion of the pain measures participants were
thanked for their time and dismissed. Due to the possibility of participant contamination
full debriefings are to be conducted at the end of the study. Participants will be
contacted by email (obtained from informed consent forms) and fully debriefed at that
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time. Table 1 indicates the characteristics of all three groups by sex, age and mean
scores for all six assessment measures.

Group

Sex
(male/female)

Age
(SD)

MSPQ
(SD)

PCS
(SD)

CTQ
(SD)

ASI
(SD)

PASS
(SD)

BDI
(SD)

Placebo

9/21

22.03
(2.9)

4.47
(3.58)

13.30
(10.51)

51.26
(8.62)

33.63
(9.43)

51.23
(12.22)

28.10
(6.48)

Nocebo

9/21

22.13
(4.2)

4.50
(3.25)

13.87
(11.30)

53.13
(6.60)

33.37
(8.10)

51.30
(11.99)

28.13
(4.61)

Control

10/20

20.16
(8.8)

4.87
(3.77)

13.10
(10.53)

54.00
(7.79)

32.57
(7.99)

48.67
(14.21)

28.60
(8.45)

Table 1. Characteristics of groups

Statistical Analysis.
MANOVA’s were conducted to establish that all three groups were equitable for
the predictor variables MSPQ, PCS and CTQ and to establish whether significant group
differences existed for the hypothesized mediating assessment measures, ASI, PASS
and BDI, respectively. Repeated measures ANOVA’s and ANCOVA’s were conducted
to evaluate mean group differences, with and without predictors, for the Hargreaves
pain measure. Latent Growth Curve Analysis and Cox Regression survival analysis
were utilized to evaluate the Ischemic arm pain measure, with and without predictors.
Differences were considered to be statistically significant at p < 0.05.
Results
A one-way MANOVA was conducted to establish whether the groups were
equitably distributed for the predictor variables MSPQ, PCS and CTQ. These three
variables were treated as dependent variables for this test. Means and standard
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deviations are presented in Table 1. Box’s Test of Equality was not significant, p > 0.7,
indicating the use of Wilk’s Criterion. The combined DV’s were not significant F(6, 170)
= .386, p=.887, indicating an equitable distribution of predictor variable scores.
Pain Measure: Hargreaves
To test the hypothesis that a difference between group assignment would be
found a one way ANOVA was conducted. Prior to running the analysis Pre and Posttest
variables for the Hargreaves were consolidated into one variable, maximum Percent
Effect (MPE). MPE allows for the clearest distinction of pre and post test scores for the
individual and was calculated with the following formula: ((test – baseline) / (20 –
baseline)) X 100. There was no significant difference between groups, F(2,54)=1.080,p
= .271. Table 2 reports the means and SD for the MPE variable.
Group

N
17

MPE
Mean
-6.7041

MPE
SD
132.17

Placebo
Nocebo

20

-135.842

393.28

Control

20

-61.515

189.860

Table 2. Means and SD for Pre MPE.

To evaluate whether the top 10 percent compared to the bottom 50 percent of
each predictor variable would identify placebo and nocebo responders a new variable
was created. The large (2008) dataset that established the number of subjects for this
study was used to establish cut off values for the MSPQ and PCS 10/50 split. Any
MSPQ score ≥ 12 and ≤4, PCS score ≥ 34 and ≤ 12, and CTQ score ≥ 65 and ≤ 51
were compiled into a single variable. Any score meeting the top 10 percent cut off was
coded a 1 and those meeting the bottom 50 percent cut off was coded 0, resulting in 61
subjects, 14 in the top 10 percent and 47 in the bottom 50 percent. After creating the
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splitting variable a new ANOVA was conducted with the splitting variable added to
group membership.. Results, once more, indicate no statistically significant difference
for group membership (F(2,48) = .727, p = .489) and an interaction of (F(2,48) = .274, p
= .761. Table 3 reports the means and (SD) for this test.
Group

10/50

N
14

MPE
Mean
-12.697

MPE
SD
145.737

50
10

3

21.263

16.696

50

13

-186.359

480.588

10

5

-79.615

103.727

50

14

-38.662

173.002

10

5

-84.669

247.046

Placebo

Nocebo

Control

Table 3. Means and SD for MPE.

Pain Measure: Ischemic Arm Test
Due to the way this test was measured two types of statistical tests were
conducted. A Latent growth curve analysis was conducted to handle pain values over
time and a Cox-Regression Survival analysis was conducted to examine survival
membership over time.
In order to establish a meaningful growth curve model a graph depicting each
groups mean pain rating over the 10 time points was evaluated (see Figure 1). After
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8
Placebo

7

Control

6

Nocebo

5
4
3
T1

T2

T3

T4

T5

T6

T7

T8

T9

T10

Figure 1, mean pain rating by group

examining the graph a piecemeal model (Figure 2) was selected for two reasons, 1) it
was believed to best represent the data, as illustrated by the means plot (figure 1) and
2) it made methodological sense as there was a participant instruction to squeeze the
hand calipers five more times between time points 5 and 6 resulting in increased pain
reporting, which is clearly represented in Figure 1. Next, two dummy variables were
created to allow clearer distinction between groups for the model. Dummy 1 represents
the placebo group and control while Dummy 2 represents the nocebo group and control.
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Figure 2, Growth Curve Piecemeal model, without predictors.

Results from the estimation of the model depicted in Figure 2 yielded

(68, N=90) =

367.430, p < .001 suggesting a poor model fit (Byrne, 2010). The RMSEA (Root Mean
Square Error of Approximation) value for this model is .222 and a CFI (Comparative Fit
Index) value of .684. Byrne (2010) suggests that a RMSEA value < .05 and a CFI value
of > .95 is recommended for good model fit. Thus it can be concluded that this model is
a poor fit of the data. Table 4 provides the regression estimates and p values for this
model.
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Icept Dummy1
1slope Dummy1
2slope Dummy1
Icept Dummy2
1slope Dummy2
2slope Dummy2

Estimate
-.164
.101
.025
.421
-.128
-.096

S.E.
.650
.149
.272
.650
.149
.272

C.R.
-.252
.678
.093
.648
-.862
-.351

p
.801
.498
.926
.517
.389
.726

Table 4

Next a model adding predictors was evaluated (see Figure 3). The first predictor
to be evaluated was MSPQ total score. Estimation results from this model yielded
(93, N=90) = 420.428, p < .001, a RMSEA value of .199 and a CFI value of .719.

Figure 3, Growth Curve Piecemeal model with predictor

Though there was some improvement in RMSEA and CFI values, results indicate this
model is a poor fit to the data. Examination of regression weights yielded no significant
p values.
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Next, a model replacing MSPQ total scores with PCS total scores was evaluated.
Estimation results for this model yielded

(93, N=90) = 407.391, p < .001, a RMSEA

value of .195 and a CFI value of .730. Examination of regression weights yielded no
significant p values.
The next model to be evaluated replaced PCS total scores with CTQ total scores.
Estimation results for this model yielded

(93, N=90) = 407.391, p < .001, a RMSEA

value of .195 and a CFI value of .730. Examination of regression weights yielded no
significant p values, however, the interaction term for placebo and CTQ trended toward
significance (see table 5).

Icept CTQ
1slope CTQ
2slope CTQ
Icept CTQ int1¹
1slope CTQ int1¹
2slope CTQ int1¹
Icept CTQ int2
1slope CTQ int2
2slope CTQ int2

Estimate
-.001
.006
.007
.094
-.022
-.043
-.034
-.002
.012

S.E.
.034
.008
.014
.055
.011
.023
.048
.011
.020

C.R.
-.029
.807
.510
1.704
-.139
-1.845
-.706
-.139
.586

p
.977
.419
.560
.088
.090
.065
.480
.890
.558

Table 5, regression weights; ¹ interaction term for CTQ and placebo.

Finally, the model depicted in Figure 3 was evaluated with the predictors MSPQ,
PCS and CTQ combined into one variable using the top 10 percent, bottom 50 percent
split described earlier. Estimation results for this model yielded

(93, N=90) =

419.260, p < .001, a RMSEA value of .199 and a CFI value of .680. Examination of the
regression weights yielded no p value that approached significance. Taken together, all
models examined exhibited poor model fit and no significant p values. Considering,
however, the trend toward significance for the interaction term of the CTQ and Placebo,
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unplanned secondary analyses were conducted on each of the five subscales
(emotional abuse, physical abuse, sexual abuse, emotional neglect and physical
neglect) to determine if any significant effect may have been washed out by only
examining a total score.
Each of the subscales were summed and centered and an interaction term
created for both Dummy1(placebo) and Dummy 2(nocebo) variables. The subscales
and their interaction terms were plugged into the model one at a time. Model fit
remained poor for all subscales, however, a significant effect was found for placebo and
physical abuse and for placebo and emotional abuse. In addition, a trend toward
significance was found for emotional neglect and nocebo. Table 6 reports these
regression weights and p values. No significant effect or trend was observed for sexual
abuse or physical neglect and were not included in the following table.
Physical Abuse
Icept Dummy 1
1slope Dummy 1
2slope Dummy 1
Icept PA x Dummy1
1slope PA x Dummy1
2slope PA x Dummy1
Emotional Abuse
Icept EA x Dummy1
1slope EA x Dummy1
2slope EA x Dummy1
Emotional Neglect
Icept EN x Dummy2
1slope EN x Dummy2
2slope EN x Dummy2

p
***
.106
.124
***
.168
.117

Estimate
-6.138
.708
1.219
.888
-.086
-.176

S.E.
1.818
.438
.792
.258
.062
.113

C.R.
-3.377
1.618
1.540
3.435
-1.378
-1.567

.519
-.092
-.178

.182
.043
.079

2.857 .004*
-2.142 .032*
-2.255 .024*

-.326
.005
.078

.178
.041
.074

-1.834 .067
.117
.907
1.052 .293

Table 6, *** p <.001; * p < .05.

Next, a Cox-Regression survival analysis was conducted to evaluate whether
ASI, PASS and BDI would predict faster dropout rates beyond that of group
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membership and the top 10, bottom 50 percent split. The dummy code variables for
group membership used in the growth curve analysis were used in this analysis as
recommended by Tabachnick and Fidell (2007) for regression analysis. Group
membership (dummy1 and dummy2) and the 10/50 split (allsplit) were entered as
covariates in the first block, ASI, PASS and BDI scores were entered into the second
block. At no time did the model become significant (

(6) = 5.753, p = .451), however,

ASI scores contributed significant variance to the prediction of dropout rates (see Table
7 for results).

Dummy1
Dummy2
Allsplit
ASI
PASS
BDI

B
.506
.402
.175
.059
-.012
-.032

SE
.487
.501
.512
.028
.018
.036

Wald
1.077
.644
.117
4.383
.438
.825

DF
1
1
1
1
1
1

Sig
.299
.422
.732
.036
.508
.364

Exp(b)
1.658
1.494
1.191
1.061
.988
.968

Table 7

Finally, no mediation tests were conducted for anxiety and depression variables
due to a lack of significance on any model examined thus far. A SOBEL mediation test
requires a significant direct path correlation before the indirect path can be examined.

Discussion
In this study, an attempt was made to identify placebo/nocebo responders based
on coping styles that were hypothesized to affect expectation. These coping styles were
described as somatization, catastrophizing and child-hood trauma all of which have
been documented to influence pain perception and outcomes (Sullivan et al., 2001;
Fillingim and Edwards, 2005; Heckman and Westefeld, 2006; Geers et al., 2006).
Additionally, an attempt was made to evaluate the extent anxiety and depression might
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mediate placebo/nocebo responsiveness. The results of planned analyses indicated
that the anxiety sensitivity index (ASI) contributed significantly to drop out rates in the
survival analysis. This is not surprising as anxiety has been repeatedly demonstrated to
influence placebo and nocebo responses, with reduced anxiety associated with placebo
effects and increased anxiety associated with nocebo effects (Benedetti et al., 2006;
2007; Colloca and Benedetti, 2007; Gatchel et al., 2007; Geers et al., 2005; Keogh et
al., 2006; Loeser and Melzack, 1999; Ploghous et al., 2001). This contribution, however,
failed to significantly improve the overall survival model and was the only component of
any planned analysis to reach significance. There was, however, an encouraging trend
found in childhood trauma scores and placebo responsiveness that warranted further
unplanned analysis.
The placebo/nocebo effect is a well-established phenomenon that has been
demonstrated using a variety of pain paradigms by numerous studies (Amanzio and
Benedetti, 1999; Benedetti, 2007; Benedetti & Amanzio, 1997; Benedetti et al., 2007;
Colloca and Benedetti, 2007; Colloca et al., 2008; Enck et al., 2008; Klosterhalfen and
Enck, 2008; Kong et al., 2008). Considering the well-established nature of the
placebo/nocebo effect it is surprising that little to no effect was observed for the
proposed hypotheses. One could reasonably conclude a methodological flaw is washing
out these primary effects.
The discussion, then, will focus on two areas. First, the author will discuss the
unplanned childhood trauma results. Second, the potential pitfalls and limitations that
may have negatively affected the outcome and suggestions for models that would
overcome these deficits are covered.
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Unplanned Analyses: Childhood Trauma
Because childhood trauma questionnaire total scores trended toward a
significant interaction between childhood trauma and placebo responsiveness further
analyses were conducted on each of the five subscales contained in the CTQ. It was
believed that such analyses might reveal effects that were washed out by the
combination of all scales into a single score.
The initial hypothesis about childhood trauma was that it would be an experience
resulting in a negative coping style, thus resulting in more susceptibility to negative
information. In this case the suggestion of pain worsening (nocebo). As mentioned
previously, research has demonstrated that early childhood trauma and adversity is
predictive for the onset of back pain in adulthood (Kopec and Sayre, 2005) and has
been related to poor outcome following back surgery (Shofferman et al., 1993).
Additionally, It is believed that childhood trauma involving abuse or neglect may
influence the way one perceives future painful events (Fillingim and Edwards, 2005;
Heckman and Westefeld, 2006) based on past experiences.
The results indicated that childhood trauma does indeed influence future painful
events. Apparently, it is not unidirectional, as the author hypothesized. Physical and
emotional abuse significantly predicted placebo responsiveness but not nocebo
responsiveness. This finding is clearly opposite to the model posited. Sexual abuse did
not influence responsiveness in either direction, nor did physical neglect. Emotional
neglect, however, trended toward nocebo responsiveness but not placebo.
It is not immediately clear why such divergence in responsiveness was found.
The literature provided the author with little information directly related to the topic.
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Fillingim and Edwards (2005) noted that subjects who self-reported sexual and physical
abuse had a decreased sensitivity to repetitive thermal stimulation but not to ischemia
pain. They also indicated that those with self-reports of abuse perceived themselves to
be in poorer health and reported greater negative affect than non-abuse groups. The
authors had no clear explanation for why there was a difference in response to brief
pain versus more intense pain. They did, however, suggest that somatic focus could be
a contributing factor. In fact, Geers et al. (2006) investigated the role of somatic focus
and placebo responding and found that individuals who were instructed to somatically
attend to a drug’s effects were more likely to be a placebo responder than those that
were not attending. This is in keeping with this study’s inclusion of somatization as a
factor in placebo/nocebo responsiveness.
It is problematic, however, in that somatization as a predictor did not produce an
effect in this study. This does not rule out the possibility that somatic focus could be a
mechanism interacting with physical and emotional abuse in such a way that
predisposes an individual to look for positive information that a painful condition is about
to be relieved. It is also possible somatic focus of negative information is an outcome of
emotional neglect. One must keep in mind that this study focused on non-clinical
populations and such a mechanism may only be temporarily effective, if it exists at all.
In a clinical pain population it may be that physical and sexual abuse then increases the
likelihood of poorer outcomes as the literature indicates.
The one clear point is that much more research needs to be conducted to
elucidate the mechanisms involved. Additionally, caution must be used in any
interpretation of this data as the population was non-clinical. This naturally resulted in
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small samples for the abuse, neglect subscales of the CTQ and could very well be
random occurrence. Though little difference was found between groups in this study as
a whole, it is encouraging that significant effects were observed for childhood trauma
and placebo/nocebo responsiveness. Even if the effects were the result of statistical
randomness further investigation is warranted, which leads to the remaining discussion
of this study’s strengths, weaknesses and suggested modifications.

Study Strengths
Although there were no significant statistical main effect findings one can still
optimistically conclude that a number of sound design elements existed in this study.
The choice of predictor variables has been demonstrated to influence pain perceptions
and outcomes (Sullivan et al., 2001; Fillingim and Edwards, 2005; Heckman and
Westefeld, 2006; Geers et al., 2006) and has been scrutinized for validity and reliability
(Main, 1983; Osman et al, 2000; Sullivan, 1995; Rosen and Martin, 1996).
Though no mediation tests could be conducted on the anxiety measures their
inclusion for consideration is in keeping with the literature. Additional support for
inclusion of anxiety measures in this study comes indirectly from the Cox Regression
survival analysis. The ASI contributed significant variance to the prediction of dropout
rates, p = .036, however, failed to bring the total model to significance. Thus, caution is
warranted in interpreting this result. That said, it could reasonably be concluded that a
similar study would benefit from the inclusion of anxiety measures.
The Hargreaves Thermal Withdrawal test is not generally conducted in
placebo/nocebo studies. However, it is the author’s opinion that inclusion of this pain
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measure can be considered a study strength for two reasons. First, the measure is brief
which allowed for a pre and posttest in the same experimental session. Second, the
following table, illustrates the differences between groups that are traditionally expected.
A clear indication the measure is sound.
Group

N
17

MPE
Mean
-6.7041

MPE
SD
132.17

Placebo
Nocebo

20

-135.842

393.28

Control

20

-61.515

189.860

Table 8. Means and SD for Pre MPE.

Inclusion of the ischemic pain measure can generally be considered a study
strength. It is a well-established measure first developed by Smith et al., (1966) and
validated by Smith et al., (1968) for use in analgesia pain studies. Since its development
it has been commonly and reliably used to detect placebo and nocebo effects,
especially by the Benedetti research group (Amanzio and Benedetti 1999; Benedetti,
1996; 1997; Benedetti et al., 1997 Benedetti et al., 2003; Benedetti et al., 2006). Further
support of this measure can be gleaned from examination of Figure 1, in which mean
scores of the VAS 10 time points are trending toward expected results.
Lastly, as noted in the introduction fewer than 4% of placebo studies have
included a no-placebo control group in which to evaluate claimed effects (Ernst and
Resch, 1995; Fisher, 2000; Geer et al., 2005). Not only did this study include a control
group the groups were conditional. Price, Finniss and Benedetti (2008) reported “Verbal
suggestions that induce certain expectations of analgesia induce larger placebo
responses than those inducing uncertain expectations.” In other words, groups that are
told what to expect (conditional) experience larger placebo effects than groups that are
36

not told what to expect (unconditional). Despite the many perceived strengths of this
study, clearly there were significant weaknesses that managed to diminish the outcome.
Study Weaknesses
Though there is no real way in which to quantify the weaknesses of this study,
reflection on the procedures used and revisiting the literature has provided the author
with several suspected deficiencies. The primary suspected deficiency was the strength
of the suggestions used. There are gradations of suggestion strength in regards to the
placebo/nocebo response. Olshansky (2007) states:
Placebo strength varies by the type of intervention. A dose response
exists. Blue (vs. pink) placebo pills are sedating. Yellow (vs. green)
placebo pills are stimulating. Red (vs. beige) placebos encourage a
cardiac response. Branded ismore effective than generic. Four-times-aday is more potent than twice-a-day. Larger capsules are stronger than
smaller ones. Interventions, injections, andsurgery give larger effects than
pills.
The above statement was echoed by Benedetti and Amanzio (1997) and Williams
(2004).
Participants in this study told that the “drugs” being investigated were of a short
duration and considered safe to take with other medications with few side effects. The
purpose of the generally weak suggestion was to alleviate participant concerns, thus
increasing participant numbers. However, reviewing the literature found Benedetti using
phrases like “powerful” and “strong” when explaining pill or injection effects (Benedetti et
al., 2006). If, as posited in the introduction, placebo and nocebo effects are contingent
on expectancies then a weak expectancy could very well have driven the weak to nonexistent results found in this study. Without a primary difference observed between
groups then all other analyses would necessarily fail.
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Though listed as strengths both pain measures also had their weaknesses that is
believed to have contributed to the difficulties observed in this study. The primary pain
measure in this study was ischemia pain induced by the tourniquet technique. This
study used a modified version of the technique described by Benedetti (1996). Amanzio
and Benedetti (1999) noted that tolerance and pain variability was observed if the
sphygmomanometer cuff was not maintained at 300mmHg and an Esmarch bandage
(pressure bandage) maintained on the forearm for the duration of the test (10 minutes).
In this study the sphygmomanometer cuff was maintained at 300mmHg,
however, due to concerns about potential participant injury an Esmarch bandage was
not applied to the forearm. In revisiting the literature the author determined a
misunderstanding about the Esmarch bandage had taken place. Originally the Esmarch
bandage was a rubber tube approximate the width of a finger and could be tightened
into a tourniquet. More recently the Esmarch bandage is a wider latex bandage, also
known as a Martin bandage, and is used primarily as a pressure bandage, not as a
tourniquet (Fletcher and Healy, 1983). The initial literature review led the author to
believe that inappropriate application of an Esmarch bandage could lead to participant
injury and was thus discarded from consideration.
Additionally, the ischemia test was only applied once. Initial consideration was
given to a repeated measures administration but was discarded for concern it would
have a significant impact on continued subject participation. In other words, there was
concern that subjects would drop from the study once they had experienced the
discomfort generated by this test. Returning to the literature has convinced the author
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that repeating this test would be the most effective technique in establishing
placebo/nocebo responses.
Finally, the ischemic arm test was measured and analyzed using a VAS pain
rating each minute over a ten minute time frame. Though this was the main measure
used by Benedetti (1996; 2006), alternative applications of this technique were modified
to be measured as length of time from last hand caliper squeeze to unbearable pain.
This measure generally induces ischemic arm pain quickly and becomes unbearable in
about 13 to 14 minutes (Amanzio and Benedetti 1999; Benedetti, 1996; 1997; Benedetti
et al., 1997 Benedetti et al., 2003; Benedetti et al., 2006). This study did not observe a
quick increase in pain. In fact, several subjects noted a lessening in discomfort after the
initial application of the blood pressure cuff. Taken together, this measure, as utilized in
this study, likely contributed significantly to the lack of effect observed between groups.
Turning next to the Hargreaves Thermal Withdrawal test, though also listed as a
strength in the study it too had observable weaknesses. During administration of the
test it was suspected that a number of subjects misunderstood the verbal instructions of
the test. Several others complained the glass top was cold to the touch and perhaps
interfered with detection of the heat stimulus. Finally, several subjects in a row timed out
on the pre and post test leading the experimenter to believe that the apparatus settings
had been altered in some fashion. In all, 25 subjects had to be eliminated for ceiling
effects on analyses that involved this test potentially contributing to non-significant
effects.
Finally, it should be considered that contamination of the subject pool may have
influenced expectations. A number of participants mentioned to the experimenter that
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they had discussed the study with other participants prior to their appointment and knew
what to expect in terms of procedure and drug strength. It is not clear to what degree, if
any, this foreknowledge may have influenced outcome.
Conclusion
The author believes that this study was fundamentally sound but
methodologically weak in the areas noted above. To address these issues two potential
study designs could be considered. First, a study primarily identical to this one with the
following changes in design. 1) Moving from a weak suggestion to a strong suggestion
and including an injection instead of a pill would largely alleviate this weakness. 2)
Modifying the ischemic arm test to include an Esmarch bandage to increase
exsanguination speed and reduce variations in pain responsiveness. 3) Moving from a
VAS measurement of pain to a time to unbearable pain measurement would likely
alleviate the considerable subjective ambiguity observed in the VAS measurement. An
instruction of “tell me when the discomfort is unbearable” is much less confusing than a
scale containing “worse pain imaginable”. It was observed that a number of subjects in
the current study gave significant consideration to the “meaning” of “worse pain
imaginable”. 4) Moving to a repeated measure of the Ischemia test would enhance
detection of effects and be more in keeping with existing literature. 5) Finally,
instructions clarifying the Hargreaves test, a daily settings check and efforts to alleviate
the “cold” sensation of the glass table top would conclude modifications to a subsequent
study based on the initial premises.
Alternatively, an animal neglect model could be proposed. Moving to an animal
model would allow more objective testing on several hypotheses considered in the
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present study. Though somatization and catastrophizing could not be directly assessed
in an animal model childhood trauma could be manipulated and its effects on pain could
be directly observed. Such a model would involve separating rat pups for extended
periods of time from their mothers to approximate emotional neglect and surgically
injuring others to approximate physical abuse. Though such manipulations might seem
cruel, an Institutional Animal Care and Use Committee (IACUC) approval has been
given at UNO for a similarly designed study.
Manipulating rearing situations and comparing them to non-manipulated animals
has the obvious advantage of control of conditions. Fewer subjects can be used
because all subjects have known histories with precisely controlled interventions. This is
unlike human studies in which larger numbers of participants are needed to obtain
adequate numbers of individuals with desired predictor variable scores. Even then,
large variations in personal histories and experiences will exist in a human subjects
study creating the possibilities that some experience or another may have been
overlooked in design consideration.
Deception is a primary component of placebo and nocebo studies. Considering
this, one might wonder how you lie to a rat. The answer would presumably be that you
violate conditioned expectations. Hernstien (1962) and Ader and Cohen (1975)
demonstrated that placebo responses could be conditioned in animals. Thus, by
extension, a model that manipulates conditioning would mimic the deception process
used in human models. For example, over the course of several trials a drug like
morphine or valium could be administered to an animal and given a saline solution
injection (placebo) on a final trial to violate expectancies. Nocebo might be
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accomplished by giving several trials of saline solution followed by Complete Freund’s
Adjuvant (CFA), a water-in-oil emulsion that contains a pain inducing agent, mimicking a
negative violation of expectancy. Though an extensive literature review is necessary to
completely work out the mechanics of an animal model it should be clear that such a
model is possible and would have distinct methodological advantages.
In summary, it is the author’s assertion that though the present study had no
significant primary findings it has a number of sound premises which was illustrated by
the unplanned CTQ analysis. A more comprehensive study built from the information
here that addresses the weaknesses mentioned by utilizing a subsequent human model
study or more precisely controlled animal model is warranted.
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